RCUS vs. MLTX, MTSR, VKTX, KYMR, MOR, CRNX, ALVO, IMVT, CPRX, and HCM
Should you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Viking Therapeutics (VKTX), Kymera Therapeutics (KYMR), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), Immunovant (IMVT), Catalyst Pharmaceuticals (CPRX), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.
Arcus Biosciences vs. Its Competitors
Arcus Biosciences (NYSE:RCUS) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.
Arcus Biosciences currently has a consensus target price of $21.29, indicating a potential upside of 158.64%. MoonLake Immunotherapeutics has a consensus target price of $74.50, indicating a potential upside of 56.84%. Given Arcus Biosciences' higher probable upside, research analysts plainly believe Arcus Biosciences is more favorable than MoonLake Immunotherapeutics.
92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Arcus Biosciences has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.
MoonLake Immunotherapeutics has lower revenue, but higher earnings than Arcus Biosciences. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.
MoonLake Immunotherapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -258.94%. MoonLake Immunotherapeutics' return on equity of -30.81% beat Arcus Biosciences' return on equity.
In the previous week, MoonLake Immunotherapeutics had 2 more articles in the media than Arcus Biosciences. MarketBeat recorded 3 mentions for MoonLake Immunotherapeutics and 1 mentions for Arcus Biosciences. MoonLake Immunotherapeutics' average media sentiment score of 0.89 beat Arcus Biosciences' score of -0.66 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.
Summary
MoonLake Immunotherapeutics beats Arcus Biosciences on 12 of the 16 factors compared between the two stocks.
Get Arcus Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcus Biosciences Competitors List
Related Companies and Tools
This page (NYSE:RCUS) was last updated on 7/8/2025 by MarketBeat.com Staff
Free RCUS Stock Alerts